572 related articles for article (PubMed ID: 30388053)
21. Differential expression of exosomal miRNAs between breast cancer patients with and without recurrence.
Sueta A; Yamamoto Y; Tomiguchi M; Takeshita T; Yamamoto-Ibusuki M; Iwase H
Oncotarget; 2017 Sep; 8(41):69934-69944. PubMed ID: 29050253
[TBL] [Abstract][Full Text] [Related]
22. Deregulation of miR-1245b-5p and miR-92a-3p and their potential target gene, GATA3, in epithelial-mesenchymal transition pathway in breast cancer.
Yadollahi Farsani M; Amini Farsani Z; Teimuri S; Kolahdouzan M; Eshraghi Samani R; Teimori H
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1955. PubMed ID: 38173189
[TBL] [Abstract][Full Text] [Related]
23. Involvement of the Dysregulation of miR-23b-3p, miR-195-5p, miR-656-5p, and miR-340-5p in Trastuzumab Resistance of HER2-Positive Breast Cancer Cells and System Biology Approach to Predict Their Targets Involved in Resistance.
Rezaei Z; Sebzari A; Kordi-Tamandani DM; Dastjerdi K
DNA Cell Biol; 2019 Feb; 38(2):184-192. PubMed ID: 30702337
[TBL] [Abstract][Full Text] [Related]
24. A ranking-based meta-analysis reveals let-7 family as a meta-signature for grade classification in breast cancer.
Oztemur Y; Bekmez T; Aydos A; Yulug IG; Bozkurt B; Dedeoglu BG
PLoS One; 2015; 10(5):e0126837. PubMed ID: 25978727
[TBL] [Abstract][Full Text] [Related]
25. Molecular pathogenesis of breast cancer: impact of miR-99a-5p and miR-99a-3p regulation on oncogenic genes.
Shinden Y; Hirashima T; Nohata N; Toda H; Okada R; Asai S; Tanaka T; Hozaka Y; Ohtsuka T; Kijima Y; Seki N
J Hum Genet; 2021 May; 66(5):519-534. PubMed ID: 33177704
[TBL] [Abstract][Full Text] [Related]
26. A two-miRNA signature of upregulated miR-185-5p and miR-362-5p as a blood biomarker for breast cancer.
Zhang K; Wang YY; Xu Y; Zhang L; Zhu J; Si PC; Wang YW; Ma R
Pathol Res Pract; 2021 Jun; 222():153458. PubMed ID: 33962174
[TBL] [Abstract][Full Text] [Related]
27. Stepwise analysis of MIR9 loci identifies miR-9-5p to be involved in Oestrogen regulated pathways in breast cancer patients.
Barbano R; Pasculli B; Rendina M; Fontana A; Fusilli C; Copetti M; Castellana S; Valori VM; Morritti M; Graziano P; Luigi C; Coco M; Picardo F; Mazza T; Evron E; Murgo R; Maiello E; Esteller M; Fazio VM; Parrella P
Sci Rep; 2017 Mar; 7():45283. PubMed ID: 28345661
[TBL] [Abstract][Full Text] [Related]
28. Prospectives of mirna gene signaling pathway in triple-negative breast cancer.
Chakkaravarthi K; Ramesh R; Palaniyandi T; Baskar G; Viswanathan S; Wahab MRA; Surendran H; Ravi M; Sivaji A
Pathol Res Pract; 2023 Aug; 248():154658. PubMed ID: 37421840
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
30. Plasma-based microRNA signatures in early diagnosis of breast cancer.
Li X; Zou W; Wang Y; Liao Z; Li L; Zhai Y; Zhang L; Gu S; Zhao X
Mol Genet Genomic Med; 2020 May; 8(5):e1092. PubMed ID: 32124558
[TBL] [Abstract][Full Text] [Related]
31. Upregulated microRNAs in membranous glomerulonephropathy are associated with significant downregulation of IL6 and MYC mRNAs.
Barbagallo C; Passanisi R; Mirabella F; Cirnigliaro M; Costanzo A; Lauretta G; Barbagallo D; Bianchi C; Pagni F; Castorina S; Granata A; Di Pietro C; Ragusa M; Malatino LS; Purrello M
J Cell Physiol; 2019 Aug; 234(8):12625-12636. PubMed ID: 30515781
[TBL] [Abstract][Full Text] [Related]
32. Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas.
Chang JT; Wang F; Chapin W; Huang RS
PLoS One; 2016; 11(12):e0168284. PubMed ID: 27959953
[TBL] [Abstract][Full Text] [Related]
33. Novel prognostic and predictive microRNA targets for triple-negative breast cancer.
Turashvili G; Lightbody ED; Tyryshkin K; SenGupta SK; Elliott BE; Madarnas Y; Ghaffari A; Day A; Nicol CJB
FASEB J; 2018 May; ():fj201800120R. PubMed ID: 29812973
[TBL] [Abstract][Full Text] [Related]
34. Gene co-expression network approach for predicting prognostic microRNA biomarkers in different subtypes of breast cancer.
Adhami M; MotieGhader H; Haghdoost AA; Afshar RM; Sadeghi B
Genomics; 2020 Jan; 112(1):135-143. PubMed ID: 30735795
[TBL] [Abstract][Full Text] [Related]
35. Tumor microRNA expression profiling identifies circulating microRNAs for early breast cancer detection.
Matamala N; Vargas MT; González-Cámpora R; Miñambres R; Arias JI; Menéndez P; Andrés-León E; Gómez-López G; Yanowsky K; Calvete-Candenas J; Inglada-Pérez L; Martínez-Delgado B; Benítez J
Clin Chem; 2015 Aug; 61(8):1098-106. PubMed ID: 26056355
[TBL] [Abstract][Full Text] [Related]
36. Claudin 1 Expression Levels Affect miRNA Dynamics in Human Basal-Like Breast Cancer Cells.
Majer A; Blanchard AA; Medina S; Booth SA; Myal Y
DNA Cell Biol; 2016 Jul; 35(7):328-39. PubMed ID: 26982264
[TBL] [Abstract][Full Text] [Related]
37. Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role.
Cochetti G; Poli G; Guelfi G; Boni A; Egidi MG; Mearini E
Onco Targets Ther; 2016; 9():7545-7553. PubMed ID: 28008272
[TBL] [Abstract][Full Text] [Related]
38. Hepatocellular carcinoma associated microRNA expression signature: integrated bioinformatics analysis, experimental validation and clinical significance.
Shi KQ; Lin Z; Chen XJ; Song M; Wang YQ; Cai YJ; Yang NB; Zheng MH; Dong JZ; Zhang L; Chen YP
Oncotarget; 2015 Sep; 6(28):25093-108. PubMed ID: 26231037
[TBL] [Abstract][Full Text] [Related]
39. Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer.
Krishnan P; Ghosh S; Wang B; Li D; Narasimhan A; Berendt R; Graham K; Mackey JR; Kovalchuk O; Damaraju S
BMC Genomics; 2015 Sep; 16():735. PubMed ID: 26416693
[TBL] [Abstract][Full Text] [Related]
40. Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma.
Wen Y; Han J; Chen J; Dong J; Xia Y; Liu J; Jiang Y; Dai J; Lu J; Jin G; Han J; Wei Q; Shen H; Sun B; Hu Z
Int J Cancer; 2015 Oct; 137(7):1679-90. PubMed ID: 25845839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
